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Dear Editors, 
Evidence has been increasing the last several 
years that oxidative modification of LDL may 
play an important role in the pathogenesis of 
atherosclerosis [1,2]. Further support for the oxi- 
dative modification hypothesis is provided by the 
recent report of Salonen et al. [3] who found that 
the titre of autoantibodies to malondialdehyde- 
modified LDL was an independent predictor of 
the progression of carotid atherosclerosis. 
Although there is little doubt about the specificity 
of these antibodies to artificially oxidised LDL [4], 
direct evidence that LDL oxidation actually takes 
place in vivo is scarce; most research on oxidation 
of LDL involves oxidisability in vitro. We have 
measured circulating cholesterol oxidation prod- 
ucts in WHHL rabbits. Six-month-old rabbits 
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(mean (& SD.) serum cholesterol 18.3 f 2.3 
IIUXlOVl, mean serum triglycerides 3.2 f 0.9 
rnmol/l) were fed with either cholesterol-free con- 
trol chow or chow mixed with the antioxidant pro- 
bucol in a low dose (10 mg/kg per day). High doses 
of probucol are known to retard atherogenesis in 
these animals [5]. One control animal died during 
the study period. After 6 months of treatment 
blood was drawn into vacutainer tubes containing 
EDTA plus 10 mg of reduced glutathione, plasma 
was prepared immediately and 0.1 mg of the anti- 
oxidant butylated hydroxytoluene added per ml. 
This treatment effectively prevents oxidation in 
vitro: in plasma of 5 normal volunteers we found 
total oxysterol levels of 1.36 pmol/l at time 0 and 
1.32 pmol/l after 6 month of storage at -80°C. 
Cholesterol oxidation products were determined 
by a modification of our previously described 
method [6]. 
The mean concentration of serum cholesterol 
was unaffected in the control animals (18.6 f 1.3 
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TABLE 1 
PLASMA LEVELS OF OXYSTEROLS (Fmol/l) IN 3 CON- 
TROL AND 4 PROBUCOL-TREATED WHHL RABBITS 
(MEAN (S.D.)) 
Control Probucol P 
Total oxysterols 9.15 (1.33) 4.64 (0.58) <O.Ol 
7a-Hydroxycholesterol 5.04 (0.33) 2.17 (0.64) c 0.001 
5,6c+Epoxycholestanol 0.78 (0.44) 0.39 (0.21) NS 
7&Hydroxycholesterol 0.69 (0.23) 0.54 (0.09) NS 
So-Cholestanetriol 0.88 (0.10) 0.55 (0.09) <O.Ol 
7-Ketocholesterol 1.41 (0.39) 0.84 (0.11) co.01 
25-Hydroxycholesterol 0.35 (0.13) 0.15 (0.02) < 0.05 
vs. 19.0 f 1.9 mmol/l), whereas there was a slight 
decrease in the probucol treated animals 
(17.7 f 2.4 vs. 14.2 & 1.8 mmol/I). Ingestion of a 
low dose of probucol caused a 50% difference in 
the levels of circulating cholesterol oxidation 
products (oxysterols) (Table 1). 
This study provides direct evidence that oxidis- 
ed lipoproteins occur in vivo in the circulation and 
that administration of low doses of probucol can 
prevent oxidation to a large extent, explaining its 
anti-atherogenic effect in WHHL rabbits. 
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